“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the...
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
About this item
Full title
Author / Creator
Vaxman, I. , Abeykoon, J. , Dispenzieri, A. , Kumar, S. K. , Buadi, F. , Lacy, M. Q. , Dingli, D. , Hwa, Y. , Fonder, A. , Hobbs, M. , Reeder, C. , Sher, T. , Hayman, S. , Kourelis, T. , Warsame, R. , Muchtar, E. , Leung, N. , Go, R. , Gonsalves, W. , Siddiqui, M. , Kyle, R. A. , Rajkumar, S. V. , Kristen, McCullough , Kapoor, P. and Gertz, M. A.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a median of eight prior lines of therapy. Six patients...
Alternative Titles
Full title
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_052538cf28fe46f1b641764536e6bd67
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_052538cf28fe46f1b641764536e6bd67
Other Identifiers
ISSN
2044-5385
E-ISSN
2044-5385
DOI
10.1038/s41408-021-00592-3
